Skip to main content
      RT @Yuz6Yusof: #ACR21 #Abstr0865 It’s time for T2T to achieve LLDAS in #lupus. In a study of N=2040 pts, mortality was

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      #ACR21 #Abstr0865 It’s time for T2T to achieve LLDAS in #lupus. In a study of N=2040 pts, mortality was 2.3% mainly due to infection. Remission off steroid was the best but only met in 14%. LLDAS-50 achieved in 48% pts and ⬇️mortality by 56% @RheumNow https://t.co/CddqMuFIOM https://t.co/g346Cbybep
      RT @DrMiniDey: Join the @RheumNow faculty tonight for a recap of Day 2 at #ACR21
      ⏰19:00 ET
      ⏰Midnight GMT- I promise

      Mrinalini Dey DrMiniDey

      4 years ago
      Join the @RheumNow faculty tonight for a recap of Day 2 at #ACR21 ⏰19:00 ET ⏰Midnight GMT- I promise to be well-caffeinated to present my many highlights from today! 😄 📺Register via the Zoom link below or watch on Youtube https://t.co/6HIQGR5T8z
      RT @drdavidliew: beautifully chaired by @cappelliMD

      also elegant talk on 'M-triad' by the always articulate @lovetolea

      David Liew drdavidliew

      4 years ago
      beautifully chaired by @cappelliMD also elegant talk on 'M-triad' by the always articulate @lovetolearn27, made me think about my pt on the ward right now! #ACR21 @RheumNow @CCalabreseDO @LCalabreseDO @got_rheum @MarieKostine @lexmeara @ReidMDMPH @NilashaGhosh @RheumDr_Nina https://t.co/2iu6zWp8Ge
      RT @MeralElRamahiMD: *️⃣CT-P13=1st monoclonal biosimilar to infliximab (IFX)
      ⭐️ReFLECT: 1370 French pts (142 RA

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      *️⃣CT-P13=1st monoclonal biosimilar to infliximab (IFX) ⭐️ReFLECT: 1370 French pts (142 RA, 411 axSpA, 96 PsA) →2 groups: IFX-naïve starting CT-P vs switching from IFX to CT-P *️⃣CT-P13 induced improvement in IFX-naïve & maintained dz in pts switched Abst#0817 #ACR21 @RheumNow https://t.co/bASmGvhuIS
      RT @drdavidliew: Great talk by @saadhealth #ACR21 & interesting to compare myocarditis irAEs to inflamm arthritis ir

      David Liew drdavidliew

      4 years ago
      Great talk by @saadhealth #ACR21 & interesting to compare myocarditis irAEs to inflamm arthritis irAEs: similar: - importance of confirming dx well - cautious adoption steroid-sparing Rx different: - clear benefit hard/early Rx - dx metrics aided by tech #ACR21 7S404 @RheumNow https://t.co/mFjM3ZlZaP
      RT @Yuz6Yusof: Catching up with #ACR21 content?🧐 Please read my article on updates of safety and effectiveness of #CO

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      Catching up with #ACR21 content?🧐 Please read my article on updates of safety and effectiveness of #COVID19 vaccines in people with #lupus @RheumNow https://t.co/pru9dTH4z7
      RT @MeralElRamahiMD: ⭐️2 polyunsaturated fatty acid lipid mediator profiles are significantly associated w/ incident

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      ⭐️2 polyunsaturated fatty acid lipid mediator profiles are significantly associated w/ incident inflammatory arthritis in ACPA+ pts ➡️If validated, this would be of great utility in determining which pts w/ pre-clinical sero+ should be treated! Abst#0590 at #ACR21 @RheumNow https://t.co/KGEwiY6G2Q
      RT @AkhilSoodMD: Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients

      Rubbert-Roth and colleagues found:
      - RA patients dev

      Akhil Sood MD AkhilSoodMD

      4 years ago
      Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients Rubbert-Roth and colleagues found: - RA patients developed anti-S1 antibodies slower and lower compared to controls - Reduced titers among Abatacept & JAKi users #ACR21 @RheumNow https://t.co/sXW8d53O8m
      Rheumatologists and Health Professionals: Join us tonight for RheumNow's #ACR21 Daily Recap at 7pm Eastern time . Regist

      Dr. John Cush RheumNow

      4 years ago
      Rheumatologists and Health Professionals: Join us tonight for RheumNow's #ACR21 Daily Recap at 7pm Eastern time . Register via the Zoom link below. https://t.co/sxQuP28APX Or visit our YouTube channel-RheumNow. https://t.co/sohrPTB16S https://t.co/LXWaBFOdHO
      RT @MeralElRamahiMD: Post-Hoc of ASCORE trial:
      ➡️RA w/ mod-high dz on SQ ABAtacept as 1st line tx w/ better retentio

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      Post-Hoc of ASCORE trial: ➡️RA w/ mod-high dz on SQ ABAtacept as 1st line tx w/ better retention vs receiving it as 2nd line tx independent of b/l duration of dz ➤Do you use ABA as 1st line treatment for RA, when/if insurance allows? Comment below! Abst#0816 #ACR21 @RheumNow https://t.co/TRJga4OfiW
      RT @bella_mehta: Cathepsin K - has some promise in Knee OA - now going to Phase 3
      @RheumNow https://t.co/exUFqcCJy1

      Bella Mehta bella_mehta

      4 years ago
      Cathepsin K - has some promise in Knee OA - now going to Phase 3 @RheumNow https://t.co/exUFqcCJy1
      ×